Recipient Comorbidity and Survival Outcomes After Kidney Transplantation: A UK-wide Prospective Cohort Study.
Adolescent
Adult
Aged
Cerebrovascular Disorders
/ epidemiology
Chronic Disease
/ epidemiology
Comorbidity
Female
Graft Rejection
/ epidemiology
Graft Survival
Heart Failure
/ epidemiology
Humans
Kidney Failure, Chronic
/ mortality
Kidney Transplantation
/ adverse effects
Liver Diseases
/ epidemiology
Male
Middle Aged
Obesity
/ epidemiology
Peripheral Vascular Diseases
/ epidemiology
Prospective Studies
Registries
/ statistics & numerical data
Risk Assessment
Risk Factors
Transplant Recipients
/ statistics & numerical data
Treatment Outcome
United Kingdom
/ epidemiology
Young Adult
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
27
8
2019
medline:
7
10
2020
entrez:
27
8
2019
Statut:
ppublish
Résumé
Comorbidity is increasingly common in kidney transplant recipients, yet the implications for transplant outcomes are not fully understood. We analyzed the relationship between recipient comorbidity and survival outcomes in a UK-wide prospective cohort study-Access to Transplantation and Transplant Outcome Measures (ATTOM). A total of 2100 adult kidney transplant recipients were recruited from all 23 UK transplant centers between 2011 and 2013. Data on 15 comorbidities were collected at the time of transplantation. Multivariable Cox regression models were used to analyze the relationship between comorbidity and 2-year graft survival, patient survival, and transplant survival (earliest of graft failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n = 1288) and living-donor kidney transplant (LDKT) recipients (n = 812). For DDKT recipients, peripheral vascular disease (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.37-6.74; P = 0.006) and obesity (HR 2.27, 95% CI: 1.27-4.06; P = 0.006) were independent risk factors for graft loss, while heart failure (HR 3.77, 95% CI: 1.79-7.95; P = 0.0005), cerebrovascular disease (HR 3.45, 95% CI: 1.72-6.92; P = 0.0005), and chronic liver disease (HR 4.36, 95% CI: 1.29-14.71; P = 0.018) were associated with an increased risk of mortality. For LDKT recipients, heart failure (HR 3.83, 95% CI: 1.15-12.81; P = 0.029) and diabetes (HR 2.23, 95% CI: 1.03-4.81; P = 0.042) were associated with poorer transplant survival. The key comorbidities that predict poorer 2-year survival outcomes after kidney transplantation have been identified in this large prospective cohort study. The findings will facilitate assessment of individual patient risks and evidence-based decision making.
Sections du résumé
BACKGROUND
Comorbidity is increasingly common in kidney transplant recipients, yet the implications for transplant outcomes are not fully understood. We analyzed the relationship between recipient comorbidity and survival outcomes in a UK-wide prospective cohort study-Access to Transplantation and Transplant Outcome Measures (ATTOM).
METHODS
A total of 2100 adult kidney transplant recipients were recruited from all 23 UK transplant centers between 2011 and 2013. Data on 15 comorbidities were collected at the time of transplantation. Multivariable Cox regression models were used to analyze the relationship between comorbidity and 2-year graft survival, patient survival, and transplant survival (earliest of graft failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n = 1288) and living-donor kidney transplant (LDKT) recipients (n = 812).
RESULTS
For DDKT recipients, peripheral vascular disease (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.37-6.74; P = 0.006) and obesity (HR 2.27, 95% CI: 1.27-4.06; P = 0.006) were independent risk factors for graft loss, while heart failure (HR 3.77, 95% CI: 1.79-7.95; P = 0.0005), cerebrovascular disease (HR 3.45, 95% CI: 1.72-6.92; P = 0.0005), and chronic liver disease (HR 4.36, 95% CI: 1.29-14.71; P = 0.018) were associated with an increased risk of mortality. For LDKT recipients, heart failure (HR 3.83, 95% CI: 1.15-12.81; P = 0.029) and diabetes (HR 2.23, 95% CI: 1.03-4.81; P = 0.042) were associated with poorer transplant survival.
CONCLUSIONS
The key comorbidities that predict poorer 2-year survival outcomes after kidney transplantation have been identified in this large prospective cohort study. The findings will facilitate assessment of individual patient risks and evidence-based decision making.
Identifiants
pubmed: 31449188
doi: 10.1097/TP.0000000000002931
pii: 00007890-202006000-00026
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1246-1255Subventions
Organisme : Department of Health
ID : RP-PG-0109-10116
Pays : United Kingdom
Références
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009; 169:342–350
Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol. 2002; 13:1918–1927
Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol. 2014; 3:156–168
NHS Blood and Transplant. UK Transplant RegistryOrgan Donation and Transplantation Annual Activity Report.Available at https://www.odt.nhs.uk/statistics-and-reports/annual-activity-report. Accessed March 7, 2019
Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol. 2005; 16:3437–3444
Chang SH, Russ GR, Chadban SJ, et al. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation. 2007; 84:611–618
Weinhandl ED, Snyder JJ, Israni AK, et al. Effect of comorbidity adjustment on CMS criteria for kidney transplant center performance. Am J Transplant. 2009; 9:506–516
Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: a comparison of comorbidity indices. Am J Kidney Dis. 2005; 46:136–142
Fabbian F, De Giorgi A, Manfredini F, et al. Impact of comorbidity on outcome in kidney transplant recipients: a retrospective study in Italy. Intern Emerg Med. 2016; 11:825–832
Grosso G, Corona D, Mistretta A, et al. Predictive value of the Charlson comorbidity index in kidney transplantation. Transplant Proc. 2012; 44:1859–1863
Kotwal S, Webster AC, Cass A, et al. Comorbidity recording and predictive power of comorbidities in the Australia and New Zealand dialysis and transplant registry compared with administrative data: 2000-2010. Nephrology (Carlton). 2016; 21:930–937
Machnicki G, Pinsky B, Takemoto S, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am j Transplant. 2009; 9:494–505
Farrugia D, Cheshire J, Begaj I, et al. Death within the first year after kidney transplantation–an observational cohort study. Transpl Int. 2014; 27:262–270
Oniscu GC, Ravanan R, Wu D, et al.; ATTOM InvestigatorsAccess to transplantation and transplant outcome measures (ATTOM): study protocol of a UK wide, in-depth, prospective cohort analysis. BMJ Open. 2016; 6:e010377
Venkat-Raman G, Tomson CR, Gao Y, et al.; ERA-EDTA RegistryNew primary renal diagnosis codes for the ERA-EDTA. Nephrol Dial Transplant. 2012; 27:4414–4419
Johnson RJ, Fuggle SV, O’Neill J, et al.; Kidney Advisory Group of NHS Blood and TransplantFactors influencing outcome after deceased heart beating donor kidney transplantation in the United Kingdom: an evidence base for a new national kidney allocation policy. Transplantation. 2010; 89:379–386
World Health OrganizationBMI Classification.Available at http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed August 7, 2019
Laubender RP, Bender R. Estimating adjusted risk difference (RD) and number needed to treat (NNT) measures in the cox regression model. Stat Med. 2010; 29:851–859
NHS Blood and TransplantOrgan Donation and Transplantation Acitivty Report 2012/13.Available at https://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2012_13.pdf. Accessed January 30, 2018
NHS Blood and TransplantOrgan Donation and Transplantation Activity Report 2011/2012.Available at https://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2011_12.pdf. Accessed January 30, 2018
Patel SI, Chakkera HA, Wennberg PW, et al. Peripheral arterial disease preoperatively may predict graft failure and mortality in kidney transplant recipients. Vasc Med. 2017; 22:225–230
Shishehbor MH, Aksut B, Poggio E, et al. Presence of peripheral artery disease in renal transplant outcomes - don’t throw the baby out with the bath water. Vasc Med. 2017; 22:231–233
Droupy S, Eschwège P, Hammoudi Y, et al. Consequences of iliac arterial atheroma on renal transplantation. J Urol. 2006; 1753 Pt 11036–1039
Cassuto J, Babu S, Laskowski I. The survival benefit of kidney transplantation in the setting of combined peripheral arterial disease and end-stage renal failure. Clin Transplant. 2016; 30:545–555
Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int. 2005; 68:2345–2351
Akolekar D, Oniscu GC, Forsythe JL. Variations in the assessment practice for renal transplantation across the United Kingdom. Transplantation. 2008; 85:407–410
Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006; 6:357–363
Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002; 73:70–74
Hill CJ, Courtney AE, Cardwell CR, et al. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015; 30:1403–1411
Lafranca JA, IJermans JN, Betjes MG, et al. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med. 2015; 13:111
Hortal L, Fernández A, Losada A, et al. Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index. Transplant Proc. 2001; 33:3110–3111
Siedlecki A, Foushee M, Curtis JJ, et al. The impact of left ventricular systolic dysfunction on survival after renal transplantation. Transplantation. 2007; 84:1610–1617
Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003; 64:603–609
Kennedy R, Case C, Fathi R, et al. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med. 2001; 110:198–204
Findlay MD, Thomson PC, MacIsaac R, et al. Risk factors and outcome of stroke in renal transplant recipients. Clin Transplant. 2016; 30:918–924
Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol. 2008; 3:1090–1101
de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006; 70:757–764
Abedini S, Holme I, Fellström B, et al.; ALERT Study GroupCerebrovascular events in renal transplant recipients. Transplantation. 2009; 87:112–117
Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant. 2003; 17:1–8
Yu TM, Lin CC, Shu KH, et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: a nationwide population-based cohort study. Sci Rep. 2016; 6:21312
Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5:1452–1461
Fabrizi F, Dixit V, Martin P, et al. Hepatitis B and survival after renal transplant: meta-analysis of observational studies. J Viral Hepat. 2014; 21:542–550
Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008; 8:593–599
Lim WH, Wong G, Pilmore HL, et al. Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes Endocrinol. 2017; 5:26–33
EBPG Expert Group on Renal TransplantationEuropean Best Practice Guidelines for Renal Transplantation. Section IV: long-term management of the transplant recipient. IV.13 Analysis of patient and graft survival. Nephrol Dial Transplant. 2002; 17Suppl 460–67
OPTN/SRTR 2016Annual Data Report: Preface. Am J Transplant. 2018; 18(Suppl 1)1–9